Posted by AGORACOM-JC
at 4:33 PM on Wednesday, February 23rd, 2022
CurrencyWorks is an Enterprise Blockchain enabling real-world solutions and opportunities for Fortune 5000 Companies.
The company targets Fortune 5000 companies with turnkey blockchain solutions to expand their market and create strategic differentiators for their businesses. These include digital currencies, payment rails, NFTs, STO’s, and the entire ecosystems around issuing and transacting these cutting-edge assets.
If that sounds complicated, it’s actually as easy as 1-2-3….
PUBLISHING (NFT’s)
Curating and housing environments and communities for the sales and transactions of NFTs on platforms, metaverses and marketplaces in a secure and regulated format ensuring transparency, credibility and mainstream adoption.
INFRASTRUCTURE (Mining)
Providing low-cost, environmentally friendly mining and cold storage services for existing customers looking to build all-inclusive solutions as well as apply to the broader market of Bitcoin and Ethereum mining.
TRANSACTIONS (Payments)
Building customized branded blockchain economies for established brands, companies and communities through crypto and digital currencies and the payment systems that power them.
What did Cameron Chell, co-head of VUELE ™ and Executive Chairman of CurrencyWorks have to say?
“We are thrilled to be offering the ZERO CONTACT Exclusive and Collector’s Edition NFTs after the successful sale of the first 11 Platinum and Elite Edition NFTs in September, which sold for more than $100,000.00. VUELE ™ will provide fans with unprecedented early access to full-length feature films, in addition to coveted movie memorabilia.”
Sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 4:40 PM on Tuesday, February 22nd, 2022
Kidoz (KIDZ: TSXV) owns the biggest mobile advertising platform for kids and families. How big? There are almost 4,000 apps around the world using Kidoz, reaching over 300 MILLION kids. The company works with top brands, including Disney, McDonald’s, Hasbro, and Lego, and is a trusted partner of Apple and Google.
Total Revenue of $5,883,484 – growth of 109% over $2,814,642 in Q3
Profit of $990,302, an increase of $1,065,342 over a loss of ($75,040) in Q3
Adjusted EBITDA of $1,353,442 – growth of 409% over $265,984 in Q3
We sat down with Kidoz Inc. Co-CEOs Jason Williams & Eldad Ben Tora to discuss their recently announced financial results.
Select Fiscal 2021 highlights:
Total Revenue of $12,433,573 – growth of 74% over 2020 Revenue of $7,148,029.
Adjusted EBITDA of $1,507,720 compared to $771,236 in fiscal 2020.
Jason Williams, Kidoz Co-CEO stated:
“Kidoz occupies the perfect position as the leader in safe contextual mobile advertising. As broadcast television continues to decline and mobile apps continue to rise, the demand for safe advertising opportunities on mobile has never been higher. Advertisers are looking for brand-safe media with the widest reach and Kidoz is the solution. Kidoz is able to work to the specific requirements of leading family brands to build awareness and create engagement with every campaign and feature product.”
KIDOZ IS A GLOBAL PLAYER
Eldad Ben Tora, Kidoz Co-CEO stated:
“In 2021 Kidoz launched campaigns for brands in 58 different countries. Kidoz has built a global solution and is represented by a global network of sales agents who know the local representatives and brands looking to reach kids and families in a safe and compliant way.
2022 IS OFF TO A RECORD START
Ben Tora added:
“While Kidoz’s growth was outstanding in 2021, management believes that we are only beginning to realize the potential of our technology and the strength of our market position …. 2022 has started at a record pace and management is confident that we will be able to continue to increase our growth. Kidoz continues to expand the number of markets in which we operate and the number of products we can monetize.”
Now sit back, relax and watch this powerful interview with Co-CEOs of Kidoz Inc.
Posted by AGORACOM-JC
at 5:44 PM on Monday, February 21st, 2022
To understand Star Navigation $SNA you first have to understand the problem they are solving.
At any given time 200-300 planes can be off the grid when flying and no one knows where they are. In an era in which GPS can easily track dogs, trains and automobiles, it’s hard to imagine that airplane tracking systems are not the strongest of all.
The Malaysian Air Flight 370 and Air France 447 disasters showed the world the weakness in plane monitoring systems … and the strong need for a real solution.
ENTER STAR NAVIGATION SYSTEMS
$SNA is a Flight Sciences Company that bridges the gap between flight experience and flight safety in real-time. In layman terms, that means the Company’s technology provides a continuous connection between planes and the ground … and the result is more than just tracking:
● Real-Time Aircraft Health and Engine Condition Monitoring
● Fuel Management System
● Fleet Management … and more
The Company’s flagship product is the STAR Airborne Data Service (STAR-ADS) which is powered by the patented STAR In-Flight Safety Monitoring System (STAR-ISMS).
Every two years, high-level government and military delegations, as well as senior corporate executives around the world attend the Singapore Airshow. As Asia’s largest Airshow, it is the place to be for leading aerospace companies and budding players eager to make their mark in the international aerospace and defense market.
Building on the Company’s progress at the Dubai Airshow, Star Navigation went into the Singapore Airshow with momentum and confidence – and if this interview is any indication, it appears that shareholders can expect meaningful sales results in 2022.
Sit back and watch this powerful AGORACOM Exclusive with Star Navigation Systems!
Posted by AGORACOM-JC
at 8:28 AM on Friday, February 18th, 2022
*AGORACOM Engagement Metrics Beat Benchmarks By 364% *AGORACOM Cashless Marketing Program Is 100% Compliant With TSXV, CSE and NEO
We are very proud to announce AGORACOM achieved another major milestone for the period December 31, 2021, when we surpassed 710 Million page views (81% AGORACOM / 19% Twitter) from 8.8 Million investors that visited 63.3 Million timesover the last 13 years.
These milestones are significant because they continue to demonstrate that AGORACOM is the primary home for serious small cap investors that want to discover their next great small cap investment. We owe much of this success to the following 2 major factors:
QUALITY OVER QUANTITY – Unlike small cap sites and major platforms that struggle with spam, profanity and overall nonsense, AGORACOM has implemented and strictly enforces it’s 6 Rules Of Use that create robust but civilized debate and discussion.
FOCUS. NOTHING BUT SMALL CAP – Despite the fact we are all in the finance industry, we don’t talk about macro finance, large cap or general economic news. Investors come to AGORACOM for just one thing – great small cap content .. and they don’t hesitate to show their love for us. AGORACOM ENGAGEMENT SHATTERS FINANCE BENCHMARKS BY 364%
AGORACOM small cap investors don’t just flip through pages, they invest a significant amount of time reading, studying and researching our small cap stocks like yours. …. And they do it far more than everywhere else. Here are the numbers:
PAGES READ PER VISIT > 364% HIGHER THAN INDUSTRY STANDARD
In a recent survey of 357 finance sites, LittleData determined the average number of pages read per visit was 2.0. The average number of pages read on AGORACOM are 9.28, which is 364% higher than the benchmark.
Moreover, when it came to the best 10% of all finance sites, AGORACOM has them beat hands down as well, with LittleData determining anything greater than 4.1 pages per visit represents the best 10% of all Finance sites. With AGORACOM registering 9.67 pages per visit for a 136% beat, it is fair to say AGORACOM is in elite status for engagement.
TIME SPENT PER VISIT > 161% HIGHER THAN INDUSTRY STANDARD
The average visitor to AGORACOM stays on the site for an average of 8 mins 23 secs. To put this into perspective, The Contentsquare Digital Experience Benchmark Report determined an average visit to financial services sites of 3 mins 13 secs, placing AGORACOM engagement 161% higher. Here are some comparables against some of the world’s biggest finance sites:
AGORACOM 8 mins 23 secs Wall Street Journal 3 mins 18 secs Marketwatch 5 mins 47 secs Motley Fool 1 mins 50 secs FOX Business 3 mins 39 secs Investing.com 5 mins 53 secs
HOW DOES AGORACOM CREATE INDUSTRY LEADING ENGAGEMENT?
The fight for investor attention is stronger than ever. Within the small cap industry investors are inundated with mountains of information from email to social media.
Moreover, the small cap industry is now facing stiff new competition for investor attention from the fast rising Web3 world of Cryptocurrencies, NFTs and Blockchains.
It’s enough to make both investors and issuers dizzy.
AGORACOM overcomes this challenge and wins the battle for investor attention by going the extra mile to create great content. While most firms communicate via “lazy linking” AGORACOM Founder and former lawyer George Tsiolis relies on his communications training to make sure the account management team delivers the following winning variety of content:
FORM – Blogs, Posts, Tweets, Comments, Videos, Audio, Graphics and GIFs
LENGTH – Ultra Long, Long, Medium, Short and Micro
PLATFORMS – YouTube, Twitter, LinkedIn, Facebook, Instagram, Spotify, Search, TikToK (yeah but no dancing!) … and of course our very own AGORACOM.com
Watch this concise but powerful 60-second video to get a great glimpse of our industry leading content machine. This unmatched variety in the form, length and distribution of our content removes all the noise for investors while providing clients with a complete digital marketing solution.
ZERO $ … AGORACOM CASHLESS AND 100% COMPLIANT PROGRAM
As a small cap company, your cash is invaluable and shouldn’t be used for anything other than operations and growth. You’ll be happy to know The AGORACOM Cashless, Shares For Services Program is fully compliant with the TSX Venture, CSE and NEO Exchanges. As such, it is considered the friendliest comp structure in the entire industry and can be summarized as follows:
Shares are issued in 5 X $20,000 installments over the twelve month term.
-Start Date -End Of Q1 -End Of Q2 -End Of Q3 -End Of Q4
-The number of shares issued is determined by the share price at each date. As the issuer share price goes higher, the number of shares issued to AGORACOM decreases.
-Each issuance comes with customary 4-month hold periods. As such, AGORACOM is a shareholder for at least 16 months (Q4 + 4 Months)
-Structure means AGORACOM becomes a long-term shareholder that is completely aligned with the Company
-$0 Cash + the full firepower of AGORACOM
CONCLUSION
Massive audience + industry leading engagement + industry leading content + $0 cash, 100% compliant shares for services
We are pleased to announce we have been selected by the Ketamine Research Foundation (KRF) to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness (Conscious Dying/Conscious Living Trial).
“This study is an important addition to the clinical care and research opportunities for patients within the Psychedelic Palliative Care program that we are building at Novamind,” said Dr. Paul Thielking, Chief Scientific Officer and Principal Investigator at Novamind’s Murray research site. “I’ve worked with this population for most of my career and, unfortunately, I’ve sometimes felt limited in what I can offer my patients to ease their emotional distress. The findings will contribute to the evidence for using KAP with patients who have a life-threatening illness and offer new insights into alternative treatments.”
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the many facets of anger. They discuss the following: how conditioning affects how we process emotions like anger, the corrective emotional experience afforded by MDMA-assisted psychotherapy and much more.
The Huntsman Cancer Institute in Salt Lake City, Utah is investigating group psilocybin therapy as a treatment for anxiety and depression in cancer patients. Dr. Paul Thielking, who serves as the study’s lead therapist, explains that even just one dose of psilocybin could entirely shift the patient’s perspective on their illness and situation. Even more remarkable? The effects of those experiences seem to last—in some case, more than four years.
Microdosing. Does it work? Amidst increased buzz around the benefits of the practice, research continues to tackle this difficult question. This week, a new double-blind study revealed that microdosing with LSD produces “negligible changes in mood and cognition”, and there has been no research on the efficacy for people suffering from anxiety and depression. Check out National Geographic’s microdosing feature to learn more about current research, perspectives, and remaining questions.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the topic of depression and whether or not psychedelic medicine can help treat it. They discuss the following: depression and suicidal ideation, ketamine treatment for depression, the qualities to look for in a professional helper, and much more.
Chief Medical Officer, Dr. Reid Robison sits down with The Dales Report to discuss his involvement in a number of studies involving ketamine and other drugs that target the same mechanisms. Many of the questions he’s asked along the way focus on safety considerations and optimal conditions for treatment.
While classic psychedelics work towards FDA approval, global drug developers are moving beyond traditional plant medicines to focus their attention on the creation of novel “precision psychedelics”, compounds with shorter trips, less side effects, and, in some cases, no hallucinogenic component. Researchers are hopeful their efforts will increase access and scalability of psychedelic treatment. “I try to think of my mom,” one COMPASS chemist explains. “If she had to have this medication, what would I want for her as an ideal compound and ideal experience?”
100,000 overdose deaths occurred in the U.S. between April 2020 and April 2021. Despite the steady rise of overdose deaths in the U.S. over the last two decades, the latest data raises an alarm about the increased need for substance use disorder prevention and treatment. Novamind recently announced plans to develop an innovative substance use disorder program. We’re also hosting a clinical trial for ketamine-assisted psychotherapy + mindfulness for opioid use disorder. Read about it here.
We are pleased to announce that, further to our press release dated December 23, 2021, we have closed our acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy.
“We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”
With the closing of the Acquisition, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, assumes the role of Medical Director at the Peoria and Phoenix clinic locations.
Mr. Edelman commented: “Joining Novamind is the right fit for our team and aligns with our mission to provide innovative and compassionate mental healthcare. I would like to thank our patients, partners and community for their ongoing support over the years. We look forward to integrating our team and operations with Novamind and benefiting from its deep expertise and infrastructure as we continue to serve a growing patient population.”
We are pleased to announce our participation in Citi’s Psychedelic Drug Video Call Series to be held virtually on January 25, 2022.
Neena Bitritto-Garg, Vice President Research Analyst, Biotech, at Citi, will host Novamind’s Chief Executive Officer, Yaron Conforti and Chief Medical Officer, Reid Robison, MD, MBA, for a fireside chat at 10:00 AM ET.
“Novamind has an established track record as a leader in commercializing psychedelic medicine and other innovative mental health therapies through a growing network of clinics and hosting an exciting pipeline of clinical trials for major drug developers,” said Mr. Conforti. “I look forward to introducing Citi’s clients to Novamind and expanding our relationships with a global base of institutional investors.”
To register for the call, please contact your Citi representative directly.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore whether or not psychedelic medicine can change your personality. They discuss the following: alter states for altered traits, “ego” and how psychedelic medicine can lead to personality changes, and much more.
In the latest issue of Mental Health Weekly, Chief Medical Officer Dr. Reid Robison discusses the benefits and barriers of psychedelic treatment and weighs in on the progress of MDMA & psilocybin research and legislative activities in the US.
Perceptions on the potential of psilocybin therapy are shifting in the medical community, according to a recent COMPASS Pathways-sponsored survey. “Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long. Physicians are looking for new approaches to accelerate the healing process, particularly for patients for whom current therapies have failed.”
A new study by Jay Nair and colleagues from MAPS PBC tries to answer the question of how psychedelic substances will be produced. This is an important step and still, “Many open questions remain about the legal framework that needs to materialize, who will distribute the medicines, and who will be qualified to provide the treatment.” Dr. Robison sat down with Mental Health Weekly for similar conversation.
Lucid News’ Itzhak Beery explores the role of shamanism in Western medicine. “Some psychotherapists feel pressured to offer this type of healing to their clients, who have heard about these magical treatments and hope for a short cut to relief. Most facilitators do not acknowledge the element of spirit or the unseen world.” We’ve also explored this question (and more) in a previous episode of the Psychedelic Frontiers Podcast. Listen to it again here.
We are pleased to unveil our clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy. The design concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.
Inclusive and welcoming, the design concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:
Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA
To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.
“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”
Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”
To see renderings of the Design Concept, click here.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Amy de la Garza. Amy is the Substance Use Disorder Program Director at Novamind and the Medical Director of the Salt Lake City clinic. Amy is a board-certified family practice physician who for the last 10 years has been providing specialized integrative healthcare for behavioral health, substance use, and a variety of other conditions.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss qualities and skills they think are essential for therapists who provide psychedelic-assisted psychotherapy.
We’re celebrating 8 months of the podcast with a GIVEAWAY on Instagram! Enter to win a sweatshirt featuring the audio waves from a fan-favorite episode of Psychedelic Therapy Frontiers.
This is big news for Canada overall. “Long-awaited amendments to Health Canada’s Special Access Program have finally been made, potentially opening the door to less onerous access to the medical access of psychedelics like psilocybin and MDMA for patients in need.” Our mission has always been to increase access to these life-changing therapies and drugs in safe and regulated settings. We celebrate this news and will continue to do our part to bring psychedelic medicine to as many people in need as possible.
PSYCH covers the year in psychedelic healthcare. “2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin.” 2021 was special, but we can’t wait to work on making 2022 even more impactful for people around the world. For more great psychedelic content from PSYCH, download the third edition of the Psychedelics as Medicine Report here.
Dr. Reid Robison and the team at Novamind have spent years providing ketamine-assisted psychotherapy and seeing the positive benefits firsthand. It’s changed the lives of thousands of our patients. We recently published a story about how ketamine helped a mother struggling with severe depression and a struggling marriage. You can read it here. Seeing the results of this systematic review by the University of Exeter is both exciting and validating. “Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.”
Posted by AGORACOM-JC
at 5:25 PM on Thursday, January 6th, 2022
The global e-commerce market surpassed $9 TRILLION in 2019 … and is scheduled to grow by a CAGR of 14% into 2027 … But mega brands control almost 70% of the US market alone and are using their strength to win even more market … making it harder for SMBs to compete in this massive market.
Logiq …. a public company for just 4 months…. is an award-winning e-commerce and fintech solutions company that is addressing that problem by helping drive e-commerce for SMBs around the world … with revenues of $37.9M in 2020 …. from 2 divisions:
AppLogiq (Agreement finalized to Transfer AppLogiq Assets into Publicly Traded Subsidiary) – In Southeast Asia AL offers a mobile application development platform as-a-service which enables hundreds of thousands of SMBs to create mobile apps with little technical expertise or know-how … Offered across Southeast Asia, Europe and U.S. in 14 languages .. …. also offers a mobile fintech payment platform (PayLogiQ) and a hyper-local food delivery service (GoLogiq)
DataLogiq – provides a data-driven, end-to-end e-commerce marketing solution that integrates AI to help SMBs in need of online marketing solutions.
Financial Highlights:
2020 revenue of $37.9 million … 31% CAGR since 2016
Revenue H1-21 $16.4 million
Revenue Q2-21 $8.3 million …
margin of 29.5%
up 16.4 percentage points from the year-ago quarter.
Revenue Q3-21 $7.8 million
margin for DataLogiq: improved from 18.9% to 28.2%.
margin for AppLogiq: improved from 12.1% to 31.7%.
Q4-21 Revenue Estimate: $12.3 million, up 87% vs Q4-20
Gross margin expected to 34.0% vs 29.5% in the previous Q / 21.1% in Q4-20
Brent Suen, president of Logiq commented,
“Our improving revenue performance throughout 2021 demonstrates our team’s commitment to driving a transformation of our business overall and providing visibility on future profitability. As we refocused our efforts on higher quality, more profitable revenue streams and adjusted to the changing market dynamics, we also drove strong gross margin improvement every quarter of 2021. In fact, our gross margin more than doubled in Q4 2021 compared to the full year of 2020.”
Suen continued,
“We believe this strong progress across the board is keeping us on the path to profitability for both of our business segments,” continued Suen. “It also advances our plans to separate our DataLogiq and AppLogiq businesses into two independent publicly traded companies as another way to further unlock shareholder value.”
Now sit back, relax and watch this powerful interview.
